{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:31:25Z","timestamp":1770903085685,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-21-21432"],"award-info":[{"award-number":["ESR-21-21432"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1245\/s10434-025-18713-8","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T19:58:05Z","timestamp":1763150285000},"page":"2230-2238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Germline BRCA1\/2 Mutation Prevalence in Unselected ER-Low\/HER2-Negative Breast Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Ji Won","family":"Yoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyoung","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong Ki","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jisun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Byoel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Gwe","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Ho","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Joo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonghan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jin","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunwoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Kyung Robyn","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai Min","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"12","key":"18713_CR1","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline update. J Clin Oncol. 2020;38(12):1346\u201366. https:\/\/doi.org\/10.1200\/JCO.19.02309.","journal-title":"J Clin Oncol."},{"issue":"9793","key":"18713_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771\u201384.","journal-title":"Lancet."},{"issue":"7","key":"18713_CR3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","volume":"30","author":"T Iwamoto","year":"2012","unstructured":"Iwamoto T, Booser D, Valero V, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30(7):729\u201334. https:\/\/doi.org\/10.1200\/JCO.2011.36.2574.","journal-title":"J Clin Oncol."},{"issue":"3","key":"18713_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10549-016-3689-z","volume":"155","author":"BS Sheffield","year":"2016","unstructured":"Sheffield BS, Kos Z, Asleh-Aburaya K, et al. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. Breast Cancer Res Treat. 2016;155(3):483\u201390. https:\/\/doi.org\/10.1007\/s10549-016-3689-z.","journal-title":"Breast Cancer Res Treat."},{"key":"18713_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100886","volume":"40","author":"B Acs","year":"2024","unstructured":"Acs B, Hartman J, Sonmez D, Lindman H, Johansson ALV, Fredriksson I. Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study. Lancet Reg Health Eur. 2024;40:100886. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100886.","journal-title":"Lancet Reg Health Eur."},{"key":"18713_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: Breast Cancer. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419 Accessed 28 May 2025"},{"issue":"2","key":"18713_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-018-5015-4","volume":"173","author":"JM Ryu","year":"2019","unstructured":"Ryu JM, Choi HJ, Kim I, et al. Prevalence and oncologic outcomes of BRCA 1\/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat. 2019;173(2):385\u201395. https:\/\/doi.org\/10.1007\/s10549-018-5015-4.","journal-title":"Breast Cancer Res Treat."},{"issue":"5","key":"18713_CR8","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/cancers12051252","volume":"12","author":"A Toss","year":"2020","unstructured":"Toss A, Molinaro E, Venturelli M, et al. BRCA detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: when biology overcomes genealogy. Cancers (Basel). 2020;12(5):1252. https:\/\/doi.org\/10.3390\/cancers12051252.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"18713_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2560.","journal-title":"Clin Cancer Res."},{"issue":"19","key":"18713_CR10","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1002\/cncr.29572","volume":"121","author":"RA Sanford","year":"2015","unstructured":"Sanford RA, Song J, Gutierrez-Barrera AM, et al. High incidence of germline BRCA mutation in patients with ER low-positive\/PR low-positive\/HER-2 neu negative tumors. Cancer. 2015;121(19):3422\u20137. https:\/\/doi.org\/10.1002\/cncr.29572.","journal-title":"Cancer."},{"issue":"5","key":"18713_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","volume":"42","author":"I Bedrosian","year":"2024","unstructured":"Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024;42(5):584\u2013604. https:\/\/doi.org\/10.1200\/JCO.23.02225.","journal-title":"J Clin Oncol."},{"key":"18713_CR12","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1545 Accessed 28 May 2025"},{"issue":"1","key":"18713_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balmana J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(1):33\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.004.","journal-title":"Ann Oncol."},{"issue":"1","key":"18713_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41698-024-00559-0","volume":"8","author":"WK Park","year":"2024","unstructured":"Park WK, Chung SY, Jung YJ, et al. Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1\/2 mutations. NPJ Precis Oncol. 2024;8(1):96. https:\/\/doi.org\/10.1038\/s41698-024-00559-0.","journal-title":"NPJ Precis Oncol."},{"issue":"16","key":"18713_CR15","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/jco-24-02263","volume":"43","author":"GM Choong","year":"2025","unstructured":"Choong GM, Hoskin TL, Boughey JC, Ingle JN, Goetz MP. Endocrine therapy omission in estrogen receptor-low (1%-10%) early-stage breast cancer. J Clin Oncol. 2025;43(16):1875\u201385. https:\/\/doi.org\/10.1200\/jco-24-02263.","journal-title":"J Clin Oncol."},{"issue":"12","key":"18713_CR16","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/jnci\/djae178","volume":"116","author":"D Massa","year":"2024","unstructured":"Massa D, Vernieri C, Nicol\u00e8 L, et al. Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer. J Natl Cancer Inst. 2024;116(12):1914\u201327. https:\/\/doi.org\/10.1093\/jnci\/djae178.","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"18713_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100289","volume":"6","author":"NM Paakkola","year":"2021","unstructured":"Paakkola NM, Karakatsanis A, Mauri D, Foukakis T, Valachis A. The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis. ESMO Open. 2021;6(6):100289. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100289.","journal-title":"ESMO Open."},{"issue":"3","key":"18713_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10549-021-06309-1","volume":"189","author":"YH Park","year":"2021","unstructured":"Park YH, Karantza V, Calhoun SR, et al. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution\u2019s experience in Korea. Breast Cancer Res Treat. 2021;189(3):653\u201363. https:\/\/doi.org\/10.1007\/s10549-021-06309-1.","journal-title":"Breast Cancer Res Treat."},{"issue":"12","key":"18713_CR19","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/genes11121469","volume":"11","author":"LA Lovejoy","year":"2020","unstructured":"Lovejoy LA, Turner CE, Wells JM, Shriver CD, Ellsworth RE. Heritability of low ER staining\/HER2-breast tumors: are we missing an opportunity for germline testing? Genes (Basel). 2020;11(12):1469. https:\/\/doi.org\/10.3390\/genes11121469.","journal-title":"Genes (Basel)."},{"issue":"7","key":"18713_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/jnci\/djz206","volume":"112","author":"HC Benefield","year":"2020","unstructured":"Benefield HC, Allott EH, Reeder-Hayes KE, et al. Borderline estrogen receptor-positive breast cancers in Black and white women. J Natl Cancer Inst. 2020;112(7):728\u201336. https:\/\/doi.org\/10.1093\/jnci\/djz206.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"18713_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-018-4948-y","volume":"172","author":"JM Ryu","year":"2018","unstructured":"Ryu JM, Choi HJ, Kim I, et al. Only estrogen receptor \u201cpositive\u201d is not enough to predict the prognosis of breast cancer. Breast Cancer Res Treat. 2018;172(3):627\u201336. https:\/\/doi.org\/10.1007\/s10549-018-4948-y.","journal-title":"Breast Cancer Res Treat."},{"key":"18713_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/CLEP.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543\u201361. https:\/\/doi.org\/10.2147\/CLEP.S206949.","journal-title":"Clin Epidemiol."},{"issue":"3","key":"18713_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10549-014-2980-0","volume":"145","author":"P Sharma","year":"2014","unstructured":"Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and\/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145(3):707\u201314. https:\/\/doi.org\/10.1007\/s10549-014-2980-0.","journal-title":"Breast Cancer Res Treat."},{"issue":"11","key":"18713_CR24","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/cncr.26576","volume":"118","author":"AR Hartman","year":"2012","unstructured":"Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787\u201395. https:\/\/doi.org\/10.1002\/cncr.26576.","journal-title":"Cancer."},{"issue":"2","key":"18713_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andre F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Ann Oncol."},{"issue":"12","key":"18713_CR26","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andre F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol."},{"issue":"6","key":"18713_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med."},{"issue":"25","key":"18713_CR28","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","journal-title":"N Engl J Med."},{"key":"18713_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","volume":"184","author":"ME Robson","year":"2023","unstructured":"Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023;184:39\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2023.01.031.","journal-title":"Eur J Cancer."},{"issue":"12","key":"18713_CR30","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.159.","journal-title":"Ann Oncol."},{"issue":"14","key":"18713_CR31","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/jco-24-01334","volume":"43","author":"M Lambertini","year":"2025","unstructured":"Lambertini M, Blondeaux E, Tomasello LM, et al. Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status. J Clin Oncol. 2025;43(14):1706\u201319. https:\/\/doi.org\/10.1200\/jco-24-01334.","journal-title":"J Clin Oncol."},{"issue":"2","key":"18713_CR32","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1200\/OP.20.00571","volume":"17","author":"J Armstrong","year":"2021","unstructured":"Armstrong J, Lynch K, Virgo KS, et al. Utilization, timing, and outcomes of BRCA genetic testing among women with newly diagnosed breast cancer from a national commercially insured population: the ABOARD study. JCO Oncol Pract. 2021;17(2):e226\u201335. https:\/\/doi.org\/10.1200\/OP.20.00571.","journal-title":"JCO Oncol Pract."},{"issue":"2","key":"18713_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10549-025-07726-2","volume":"212","author":"AM Kostov","year":"2025","unstructured":"Kostov AM, Jensen MB, Ejlertsen B, et al. Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study. Breast Cancer Res Treat. 2025;212(2):309\u201323. https:\/\/doi.org\/10.1007\/s10549-025-07726-2.","journal-title":"Breast Cancer Res Treat."},{"issue":"6","key":"18713_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108324","volume":"50","author":"C Apostolova","year":"2024","unstructured":"Apostolova C, Ferroum A, Alhassan B, et al. Timing of genetic testing in BRCA1\/2 and PALB2-Associated breast cancer: preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy. Eur J Surg Oncol. 2024;50(6):108324. https:\/\/doi.org\/10.1016\/j.ejso.2024.108324.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"18713_CR35","doi-asserted-by":"publisher","first-page":"14747","DOI":"10.1038\/s41598-021-94195-4","volume":"11","author":"J Woo","year":"2021","unstructured":"Woo J, Gwak G, Park I, et al. Preoperative diagnosis of BRCA1\/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients. Sci Rep. 2021;11(1):14747. https:\/\/doi.org\/10.1038\/s41598-021-94195-4.","journal-title":"Sci Rep."},{"issue":"1","key":"18713_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41523-024-00686-8","volume":"10","author":"P Dubsky","year":"2024","unstructured":"Dubsky P, Jackisch C, Im SA, et al. BRCA genetic testing and counseling in breast cancer: how do we meet our patients\u2019 needs? NPJ Breast Cancer. 2024;10(1):77. https:\/\/doi.org\/10.1038\/s41523-024-00686-8.","journal-title":"NPJ Breast Cancer."},{"issue":"9","key":"18713_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.32725","volume":"7","author":"L Sun","year":"2024","unstructured":"Sun L, Wei X, Fierheller CT, et al. Economic evaluation of population-based BRCA1 and BRCA2 testing in Canada. JAMA Netw Open. 2024;7(9):e2432725. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.32725.","journal-title":"JAMA Netw Open."},{"key":"18713_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100849","volume":"2","author":"DG Evans","year":"2024","unstructured":"Evans DG, Woodward ER, Burghel GJ, et al. Population-based germline testing of BRCA1, BRCA2, and PALB2 in breast cancer patients in the United Kingdom: evidence to support extended testing, and definition of groups who may not require testing. Genet Med Open. 2024;2:100849. https:\/\/doi.org\/10.1016\/j.gimo.2023.100849.","journal-title":"Genet Med Open."},{"key":"18713_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.breast.2021.04.011","volume":"58","author":"F Ficarazzi","year":"2021","unstructured":"Ficarazzi F, Vecchi M, Ferrari M, Pierotti MA. Towards population-based genetic screenings for breast and ovarian cancer: a comprehensive review from economic evaluations to patient perspectives. Breast. 2021;58:121\u20139. https:\/\/doi.org\/10.1016\/j.breast.2021.04.011.","journal-title":"Breast."},{"issue":"11","key":"18713_CR40","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.annonc.2021.08.1988","volume":"32","author":"S Schrodi","year":"2021","unstructured":"Schrodi S, Braun M, Andrulat A, et al. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol. 2021;32(11):1410\u201324. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1988.","journal-title":"Ann Oncol."},{"issue":"5","key":"18713_CR41","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/annonc\/mdu053","volume":"25","author":"M Yi","year":"2014","unstructured":"Yi M, Huo L, Koenig KB, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol. 2014;25(5):1004\u201311. https:\/\/doi.org\/10.1093\/annonc\/mdu053.","journal-title":"Ann Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18713-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18713-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18713-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:40:25Z","timestamp":1770900025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18713-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18713"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18713-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. It was approved by the institutional review boards (IRBs) of SMC, AMC, SNUH, and GSH, Seoul, Korea (IRB no. SMC 2021-08-084, AMC 2024-0386, SNUH 2203-052-1303, GSH 3-2023-0350). The requirement for informed consent was waived due to the minimal risk nature of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}